Introduction
============

Early gastric cancer (EGC) carries a definite risk of progression and affects survival [@JR1170-1] [@JR1170-2] . However, we sometimes experience a subset of gastric cancer (GC) which progresses very slowly. Information regarding the natural history of EGC may be useful in various clinical situations because older patients, those with limited life expectancy, or those at high operative risk should be informed about the expected outcomes for non-operative management of GC.

Non-operative management is divided into endoscopic treatment, no treatment with follow-up, and no follow-up. Even if curing the lesion is difficult, endoscopic treatment may be performed at the patient's request because tumor reduction may delay appearance of symptoms and relieve pain. No follow-up is chosen when EGC is considered not to be a prognostic factor for reasons such as other cancers or diseases. No treatment with follow-up is selected when endoscopic treatment is not performed for reasons such as the patient's advanced age or poor general condition. In this case, the natural history of EGC helps treatment decision-making. However, there have been few reports on the natural history of EGC, especially regarding early-stage cancer.

Therefore, we aimed to investigate progression of EGC in Japan, mainly mucosal cancer (i. e., mucosal high-grade neoplasia \[HGN\] in Western countries) and to clarify the natural history of EGC based on endoscopic follow-up data.

Case reports
============

This was a retrospective study conducted at the Osaka International Cancer Institute. Patient inclusion criteria were as follows: (1) endoscopically diagnosed mucosal or submucosal lesion; (2) histologically diagnosed adenocarcinoma on biopsy specimen; (3) no surgical or endoscopic resection for more than 1 year; (4) no exposure to chemotherapy or radiation for GC or other primary cancers; and (5) one or more endoscopic follow-ups.

Follow-up endoscopic examinations were conducted mainly to monitor progression of cancer. Depth of tumor invasion was determined by endoscopic findings, such as thickness of the lesion, stiff protrusion, marginal elevation, remarkable redness, and irregularity of the surface [@JR1170-3] [@JR1170-4] . Deep progression (DP) was defined as submucosal invasion by a mucosal tumor and proper muscle invasion by a submucosal tumor. Lateral progression (LP) was defined as ≥ 20 % increase in size. The size of lesions was estimated by comparison with the known diameter of an endoscope or open forceps.

Vital status and causes of death were confirmed by medical charts. Patients who died from causes other than GC were regarded as censored at the time of death. Patients with unknown vital status were also treated as censored at the time when they were last known to be alive. Time to progression was measured from date of diagnosis to first date of deep progression or lateral progression. The time-to-progression curve was generated using the Kaplan-Meier method. Statistical analysis was carried out by R version 3.3.3 ( <http://www.r-project.org> ).

Twenty-one lesions fulfilled all the inclusion criteria ( [Fig. 1](#FI1170-1){ref-type="fig"} ). A summary of characteristics of the patients and lesions is shown in [Table 1](#TB1170-1){ref-type="table"} . The follow-up rate was 67 % (68 /102) and that for more than 1 year was 29 % (30 /102). The reasons for no treatment with follow-up were an obfuscated lesion in five patients, refusal of the patient in six cases, other primary advanced cancers in eight, and other serious disease in two patients. Among 34 patients with no treatment and no follow-up, the reasons were other primary advanced cancer in seven, poor nutrition in one, and unknown in 26 patients. Results of an endoscopic examination and progression are shown in [Table 2](#TB1170-2){ref-type="table"} . Median follow-up periods for intramucosal and submucosal cancers were 26.5 and 16 months, respectively. Of 18 mucosal tumors, one showed DP and six showed LP. Of three submucosal tumors, two showed DP and three showed LP.

![ Diagram showing patient enrollment.](10-1055-a-0746-3329-i1170ei1){#FI1170-1}

###### Summary of 21 EGC cases.

  Case   Sex   Age   Reasons for no treatment   Endoscopic follow-up period (month)   Number of endoscopic examinations   Initial findings   LP or not   DP or not   Outcome   Depth of invasion in the resected specimens                                                 
  ------ ----- ----- -------------------------- ------------------------------------- ----------------------------------- ------------------ ----------- ----------- --------- --------------------------------------------- ----- ----- --------------------------------- ---
   1     M     79    Once obfuscated             32                                   7                                   M                  IIa         M            6        Tub1                                          Yes   No    ESD                               M
   2     M     93    With other cancer           27                                   4                                   U                  IIa         M            8        Tub1                                          No    No    Unknown                           
   3     M     71    With other cancer           13                                   2                                   L                  IIc         M           15        Sig                                           Yes   No    Death from esophageal cancer      
   4     M     85    Obfuscated                  26                                   3                                   U                  IIc         M            4        Tub2                                          No    No    Alive without treatment for EGC   
   5     M     76    With other cancer           16                                   2                                   M                  IIc         SM          50        Tub2                                          Yes   Yes   Unknown                           
   6     F     63    With other cancer           17                                   3                                   L                  IIc         M            5        Por                                           No    No    Death from gynecologic cancer     
   7     M     72    Obfuscated                  38                                   6                                   L                  IIc         M            5        Tub1                                          No    No    Alive without treatment for EGC   
   8     M     76    No wish for treatment       14                                   1                                   L                  IIc         M            6        Tub1                                          Yes   No    Alive without treatment for EGC   
   9     M     86    Obfuscated                  19                                   3                                   L                  IIc         M            8        Tub1                                          No    No    Alive without treatment for EGC   
  10     M     72    With other cancer           16                                   3                                   L                  IIa         M           10        Tub1                                          Yes   Yes   Death from esophageal cancer      
  11     M     67    No wish for treatment      110                                   9                                   L                  IIa         M           10        Tub1                                          No    No    Alive without treatment for EGC   
  12     M     59    With other disease          16                                   3                                   L                  IIc         SM          30        Tub1                                          Yes   No    ESD for EGC, but death from HCC   M
  13     M     73    With other cancer           41                                   6                                   L                  IIa         M            8        Tub1                                          Yes   No    Alive without treatment for EGC   
  14     M     77    No wish for treatment       52                                   5                                   L                  IIa         M            6        Tub1                                          No    No    ESD                               M
  15     M     48    With other cancer           37                                   3                                   L                  IIc         M           20        Sig                                           No    No    Death from lung cancer            
  16     F     90    No wish for treatment       21                                   4                                   L                  IIc         M           15        Tub1                                          No    No    Unknown                           
  17     F     78    No wish for treatment       41                                   4                                   L                  IIc         M           10        Tub1                                          No    No    ESD                               M
  18     M     71    Obfuscated                  31                                   3                                   L                  IIa         M            4        Tub1                                          No    No    Alive without treatment for EGC   
  19     M     55    With other disease          17                                   1                                   L                  IIc         M            8        Tub1                                          Yes   No    ESD                               M
  20     M     79    No wish for treatment       23                                   2                                   L                  IIa         M            3        Tub1                                          No    No    Alive without treatment for EGC   
  21     M     80    With other cancer           18                                   3                                   L                  IIc         SM          30        Tub2                                          Yes   Yes   Unknown                           

EGC, early gastric cancer; LP, lateral progression; DP, deep progression; M, middle thirds of stomach; U, upper thirds of stomach; L, lower thirds of stomach; IIa, superficial elevated type; IIc, superficial depressed type; M, intramucosal cancer; SM, submucosal cancer; Tub1, well differentiated tubular adenocarcinoma; Tub2, moderately differentiated tubular adenocarcinoma; por, poorly differentiated adenocarcinoma; sig, signet ring cell carcinoma; HCC, hepatocellular carcinoma

###### Results of endoscopic examination and progression.

                                                          n = 21                     
  ------------------------------------------------------- -------------------------- ----------------------------
  Endoscopic follow-up period, median (range), months     23 (13 -- 110)             
  Number of endoscopic examinations, median (range)       3 (1 -- 9)                 
                                                          Mucosal cancers (n = 18)   Submucosal cancers (n = 3)
  Lateral progression, n(%)                               6 (33)                     3 (100)
  Deep progression, n(%)                                  1 (6)                      2 (67)
  Median degree of lateral progression                    50 %                       67 %
  Cumulative 1- and 3-year risk for lateral progression   6 % and 31 %               Both 100 %
  Cumulative 1- and 3-year risk for deep progression      0 % and 6 %                33 % and 100 %

Clinical course of two progressive cases
----------------------------------------

### Patient 5

The lesion was estimated to be submucosal cancer because of SMT (submucosal tumor)-like marginal elevation ( [Fig. 2a](#FI1170-2){ref-type="fig"} ). Twelve months later, it was up to 100 mm and the depression progressed more deeply ( [Fig. 2b](#FI1170-2){ref-type="fig"} ). Sixteen months later, the elevation became more obvious. The lesion was finally estimated to be cancer invading into the muscularis propria or deeper ( [Fig. 2c](#FI1170-2){ref-type="fig"} ).

![ Case 5: Lesion with lateral progression and deep progression (submucosal cancer to advanced cancer).](10-1055-a-0746-3329-i1170ei2){#FI1170-2}

### Patient 21

The lesion was estimated to be submucosal cancer ( [Fig. 3a](#FI1170-3){ref-type="fig"} ) by the thickness and marginal elevation. Twelve months later, it was up to 50 mm and estimated to be muscularis propria cancer because the thickness and elevation became more obvious ( [Fig. 3b](#FI1170-3){ref-type="fig"} ).

![ Case 21: Lesion with lateral progression and deep progression (submucosal cancer to advanced cancer).](10-1055-a-0746-3329-i1170ei3){#FI1170-3}

Clinical course of a dormant case
---------------------------------

### Patient 11

The lesion was initially diagnosed as intramucosal cancer, ( [Fig. 4a](#FI1170-4){ref-type="fig"} ) and the diagnosis has remained mucosal cancer for 110 months ( [Fig. 4b](#FI1170-4){ref-type="fig"} ).

![ Case 11: The lesion was initially diagnosed as intramucosal cancer, and the diagnosis has remained mucosal cancer for 110 months.](10-1055-a-0746-3329-i1170ei4){#FI1170-4}

Discussion
----------

In our case series, only one of 18 mucosal tumors showed DP and six showed LP. Of three submucosal tumors, two showed DP and three showed LP.

Several studies have investigated the natural history of noninvasive gastric neoplasia based on histological follow-up data in a Western population. A report from Italy showed that 17 % of noninvasive neoplasias had evolved to invasive GC during an average follow-up of 52 months [@JR1170-5] . A study from the Netherlands reported an annual incidence of invasive GC of 0.6 % for mild-to-moderate dysplasia and 6 % for severe dysplasia [@JR1170-6] . These data provide important information because intramucosal invasive cancer of the stomach, unlike intramucosal carcinoma of the colon, metastasizes. However, the distinction between intramucosal invasive cancer and HGN or carcinoma in situ can be challenging when evaluated by histological examination of the mucosal surface. Considering that these studies were based on biopsy specimens taken from the surface of mucosa, the reliability of differential diagnosis of invasive or noninvasive neoplasm is limited.

In another study, progression of EGC was investigated based on endoscopic follow-up data in a Japanese population [@JR1170-7] . This report from Osaka showed a cumulative 5-year risk of progression to the advanced stage of 63.0 % in 71 patients. However, in this study, initial depth of tumor invasion was not differentiated into mucosal and submucosal cancer. Because mucosal cancer in Japan includes noninvasive neoplasia, risk of progression to advanced cancer may differ substantially between mucosal and submucosal cancer. In the current study, only one of 18 mucosal cancers (mucosal HGN in Western countries) showed DP and six showed LP. These results suggest that a certain proportion of mucosal tumors can lie dormant for several years.

When we consider the implications of DP and LP, DP is equivalent to advancement of the T category (i. e., T1a to T1b or T1b to T2). The T category is a main component of TNM staging and is associated with GC prognosis [@JR1170-8] [@JR1170-9] . However, LP is not a component of TNM staging, and the relationship with prognosis remains unclear. However, lesion size is a significant predictive factor for metastasis [@JR1170-8] and may indirectly be associated with prognosis. Based on these findings, DP and LP are considered in oncological terms as worsening.

The inclusion process for patients without treatment may be biased by some factors. A detailed database would help to identify all patients who fulfill the study criteria. Most hospitals may have a database of patients who have received treatment, but no such register for those not undergoing treatment. Another data source may then be used to identify the patients without treatment, such as medical charts or endoscopic records. However, untreated patients with short follow-up would be missed because they may have fewer follow-up visits or examinations. To overcome these shortcomings, we used the cancer registry to identify untreated patients with GC. This registry integrates histology, treatment, drug, and accounting databases, and includes dates of diagnosis and treatment. By combining multiple databases, the cancer registry can accumulate more patients than a single database and thus minimize the risk of overlooking patients with cancer. By referral to dates of diagnosis and treatment in the cancer registry, patients with no treatment or delayed treatment can be identified.

There are some limitations to the current study. The first limitation is the small number of patients. GC comprises a heterogeneous group of diseases with various histological types (differentiated or undifferentiated) and morphological types (elevated or depressed). Risk of progression may differ among these forms. However, the potential predictive factors for progression were not identified in our study because of the limited number of progressive cancers. A median follow-up of 23 months might be insufficient to clarify the natural history of GC, especially in revealing whether this type of cancer progresses to eventual death.

Another limitation is the low follow-up rate of 67 % in this study. The follow-up rate, a standard index of completeness, is important for assessing the validity of a cohort study [@JR1170-10] . However, we consider the follow-up rate in this study was low because most patients with no treatment returned to previous doctors. The other limitation is that the judgement of DP, particularly for progression from submucosal cancer to proper muscle invasion, is difficult and can be subjective.

Conclusion
==========

In conclusion, our study suggests that a certain proportion of mucosal cancers can lie dormant for several years. Further large-scale studies in a multicenter setting should help to overcome the limitations of this study.
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